{
    "id": 28255,
    "fullName": "FGFR2 C383R",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 C383R (corresponds to as C382R in the canonical isoform) lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). C383R has not been biochemically characterized, however, C382R results in Fgfr2 autophosphorylation and transformation in culture and therefore, C383R is predicted to confer a gain of function (PMID: 9136983).",
            "references": [
                {
                    "id": 2114,
                    "pubMedId": 9136983,
                    "title": "Activation of FGF receptors by mutations in the transmembrane domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9136983"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "C383R",
    "createDate": "05/13/2018",
    "updateDate": "05/30/2019",
    "referenceTranscriptCoordinates": {
        "id": 175974,
        "transcript": "NM_022970",
        "gDna": "chr10:g.121515260A>G",
        "cDna": "c.1147T>C",
        "protein": "p.C383R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3288,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an endometrial cancer cell line harboring FGFR2 C383R and expressing FGFR2 N550K demonstrated resistance when treated with PD173074 (PMID: 23908597).",
            "molecularProfile": {
                "id": 29845,
                "profileName": "FGFR2 C383R FGFR2 N550K"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 C383R, PIK3CA E978K and V344G, PIK3R1 N707del, and PTEN mutant in culture, and tumor regression in xenograft models (PMID: 28119489).",
            "molecularProfile": {
                "id": 29846,
                "profileName": "FGFR2 C383R PIK3CA V344G PIK3CA E978K PIK3R1 N707del PTEN mut"
            },
            "therapy": {
                "id": 1293,
                "therapyName": "Alpelisib + BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10772,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 C383R, PIK3CA E978K and V344G, PIK3R1 N707del, and PTEN mutant in culture, and tumor regression in xenograft models (PMID: 28119489).",
            "molecularProfile": {
                "id": 29846,
                "profileName": "FGFR2 C383R PIK3CA V344G PIK3CA E978K PIK3R1 N707del PTEN mut"
            },
            "therapy": {
                "id": 5613,
                "therapyName": "BGJ398 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10775,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 C383R, PIK3CA E978K and V344G, PIK3R1 N707del, and PTEN mutant in culture (PMID: 28119489).",
            "molecularProfile": {
                "id": 29846,
                "profileName": "FGFR2 C383R PIK3CA V344G PIK3CA E978K PIK3R1 N707del PTEN mut"
            },
            "therapy": {
                "id": 5612,
                "therapyName": "BGJ398 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29844,
            "profileName": "FGFR2 C383R",
            "profileTreatmentApproaches": [
                {
                    "id": 18586,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 C383R"
                },
                {
                    "id": 18585,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 C383R"
                }
            ]
        },
        {
            "id": 29845,
            "profileName": "FGFR2 C383R FGFR2 N550K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29846,
            "profileName": "FGFR2 C383R PIK3CA V344G PIK3CA E978K PIK3R1 N707del PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 175974,
            "transcript": "NM_022970",
            "gDna": "chr10:g.121515260A>G",
            "cDna": "c.1147T>C",
            "protein": "p.C383R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 175975,
            "transcript": "NM_001144913",
            "gDna": "chr10:g.121515260A>G",
            "cDna": "c.1147T>C",
            "protein": "p.C383R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}